This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Monitoring for safety

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Gold therapy is potentially toxic and therefore the drug must be carefully monitored.

FBC, U&Es, urine dipstick Every 2 weeks until stable; then before each injection

Before each injection:

  • FBC (watch Hb, MCV, Differential WCC & platelets for trends as well as absolute levels) - give injection only if previous result is available and satisfactory
  • urinalysis for proteinuria or haematuria

ESR is monitored monthly.

Stop drug, inform specialist if:

  • rash or mouth ulcers
  • WBC < 3.5 x10^9/l
  • platelets < 150 x 10^9/l
  • haematuria or proteinura on two or more occasions - inform specialist, order MSU and 24-hour urinary protein

If suspicious symptoms or signs:

  • urgent FBC if there are symptoms of infection(leucopenia)
  • urgent platelets if bruising, bleeding(thrombocytopenia)

Ideally results should be recorded in a patient-held booklet

Reference:

  1. Doctor magazine(December 2002). Disease-modifying anti-rheumatic drugs
  2. MeReC Bulletin 2007;17(5):1-8.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.